Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Novartis ends ALS program after phase 2 flop, adding to R&D woes
(19h)
Novartis pays Sironax $125M to acquire platform for crossing the blood-brain barrier
(21h)
Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial
(1d)
FDA launches pilot program to speed up sluggish phase 1 trials
(1d)
Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope
(1d)
Mayo Clinic teams with Thermo Fisher to form biomedical data group Precure
(1d)
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
(1d)
Newly formed Jaguar acquires Afib device assets from JJ
(1d)
Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail
(2d)
GSK doubles down on Chimagen with $750M multiple myeloma wager
(2d)
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
(2d)
After rejection, FDA approves Telix’s Pixclara, the first FET-PET imaging drug for brain cancer
(2d)
J&J’s Contineum-partnered depression drug flunks another phase 2 test
(2d)
As ‘cultural weight’ of a psychedelic approval looms, FDA hearing focuses on access and safety
(2d)
Lilly cans early experimental obesity drug after ‘high bar’ not met
(2d)
Axoltis misses the mark in phase 2 ALS study, but still strives to move towards the clinic
(2d)
Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi
(2d)
Electra aims for $342M IPO to power inflammatory drug’s push through phase 3
(2d)
No more Nordisk as Novo goes it alone amid rebranding push
(3d)
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
(3d)
BioPharma Dive
Novartis to pay $125M for blood-brain barrier crossing platform
(13h)
Novo looks to Anthropic’s AI models to ‘supercharge’ drug development
(18h)
Sling banks $123M for an experimental thyroid eye disease pill
(18h)
Skyhawk racks up more support for Huntington’s drug
(20h)
FDA clears first generic radioligand drug; Sionna turns to layoffs
(1d)
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
(1d)
FDA launches pilot program to speed up early US drug research
(1d)
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
(2d)
AstraZeneca’s newly approved pill fails frontline breast cancer study
(2d)
Cellectis quits CAR-Ts and pivots to ‘in vivo’ gene editing
(2d)
Scholar Rock SMA drug approved by FDA
(2d)
This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
(5d)
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
(5d)
mRNA cancer vaccines’ biggest barriers to market
(5d)
FDA places partial hold on Biohaven’s epilepsy drug
(6d)
Andy Plump, architect of Takeda’s R&D overhaul, to retire next year
(6d)
A booming business on Wall Street would love more biotechs to quietly die
(7d)
Tyra disappoints investors with bladder cancer data
(1w)
Kura spins diabetes work into a Lilly-backed biotech startup
(1w)
FDA gains ‘continuity’ as Mikhail, Davis named permanent CBER, CDER leaders
(1w)
Endpoints News
Drugmakers cooperate with House probe of China trial sites
(15h)
FDA faces questions on 'America First' provisions in latest user fee agreement
(16h)
Gilead reaches HIV PrEP agreements; Hong Kong investigates Cloudbreak IPO
(18h)
Researchers implant human neurons in mice brains to study disease
(18h)
Novo signs Anthropic deal to test Claude Science in RD
(19h)
Novartis' TREM2 drug fails Phase 2 ALS trial
(22h)
Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease
(22h)
Skyhawk says its Huntington’s drug improved symptoms in extension to Phase 1/2 trial
(22h)
Klomp, Warren spar over MFN deal contracts
(1d)
FDA approves first radioligand generic, setting up rivalry with Novartis
(1d)
Centric Compounding recalls three injectables over contamination
(1d)
Sionna cuts nearly half of staff as it lines up second attempt at cystic fibrosis
(1d)
Rocket's Danon plans; Novo leaves Ascendis; Lilly's latest deal
(1d)
FDA leaders say they've woven feedback into new trial pilot
(1d)
Axoltis says its Phase 2 study for an experimental ALS drug failed
(1d)
Why Omada is staying in its lane
(1d)
Kairon Health raises $5M to use data to make patients healthier
(1d)
GSK strikes deal for Chimagen’s T cell engager for blood cancer
(2d)
Vera eyes full approval for Trutakna in IgAN following positive readout
(2d)
RegCell lands $44M Series A to take Nobel-winning Tregs into clinic
(2d)
BioSpace
Biopharma hiring hotspots: States, disciplines where demand is highest
(2h)
Trending: Top biopharma disciplines with jobs live now
(2h)
FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation
(19h)
Deep dive: Psychedelics back on FDA’s doorstep
(19h)
Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month
(20h)
Sling catches $123M series C for thyroid eye disease pill
(21h)
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
(23h)
AI is changing the talent biotech companies compete to hire
(1d)
For many, the retirement goal posts are shifting
(1d)
5 biotechs braving the commercial waters with product launches
(1d)
FDA opens Operation TrialBlazer for applications, hoping to reshore early trials
(1d)
Rare disease reform, CMC risk, reshoring US trials top of mind ahead of PDUFA VIII meeting
(1d)
Stakeholders urge FDA to define data, treatment standards as psychedelic drugs near market
(1d)
Despite 3 patient deaths, Cullinan, Taiho plan FDA filing for lung cancer pill on survival benefit
(1d)
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
(1d)
GSK lays off 650 staffers amid closure of German vaccine manufacturing site
(1d)
Blood centers can help biopharma scale cell and gene therapies
(2d)
AAM sounds alarm on ‘unsustainable, race to the bottom’ for generics and biosimilars
(2d)
Report: The Insider's Guide to Thought Leadership in Biopharma
(2d)
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
(2d)
STAT News
The FDA’s rebuilding effort is running into a new challenge
(1h)
What happened to oppositional defiant disorder?
(1h)
England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal
(2h)
New lawsuit argues NIH violated First Amendment rights of grant applicants
(9h)
GOP aims to change Medicare adviser’s math to help out private insurers
(13h)
Senators highlight the power Chris Klomp wields at confirmation hearings
(14h)
WHO expresses cautious optimism about bid to control Ebola outbreak in DRC
(17h)
Scientists made mice with half a brain. Then they filled them with human organoids
(18h)
Sen. Warren demands to see Trump drug-pricing pharma contracts, accuses RFK Jr. of hiding them
(20h)
We’re reading about faster FDA approvals, access to experimental drugs in Montana, and more
(20h)
U.S. reaches highest number of measles deaths in decades
(21h)
House Democrats may use oversight powers to plan for health care overhaul
(1d)
How my cancer diagnosis changed the way I train physicians
(1d)
Dementia should be a campaign issue — not an insult
(1d)
A fourth measles death is reported in Pennsylvania
(1d)
RFK Jr. returns to his roots
(1d)
Medicare to expand its pilot that pays for technology to manage chronic diseases
(1d)
FDA takes applications for new program to shorten drug approval times
(1d)
Obesity drugmakers are testing in kids as young as 6
(1d)
We’re reading about a GSK deal for a drug from China, job losses in the U.S., and more
(1d)
BioPharma Trend
The Bigger Point Beyond Insilico's Aging Research Milestone
(1w)
The Measurement Challenge in Longevity: Can Aging Biomarkers and Clocks Close the Gap?
(1w)
What the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences
(2w)
Into the Dark: Finding Novel Drug Targets Within the Depths of Our Proteome
(2w)
Beyond the Code: How DNA Nanotechnology is Moving from Molecular Origami to Programmable Biotech Platforms
(4w)
Seven HealthTech Trends In Europe To Watch
(2mo)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(3mo)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(3mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(4mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(5mo)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(5mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(5mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(5mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(5mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(5mo)
Enveda’s AI-Discovered Drug Shows Early Atopic Dermatitis Relief
(5mo)
Lilly Signs $2.75B AI Drug Discovery Deal With Insilico
(5mo)
Meta Open Sources Foundation Model That Predicts Brain Responses to Speech, Video, and Text
(5mo)
Two Ex-GSK AI Leads Go Stealth with a New Oncology Drug Discovery Startup
(5mo)
Tempus and Daiichi Sankyo Partner on AI-Guided Cancer Biomarker Discovery
(5mo)
Drug Channels
Preorder DCI’s New 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
(2d)
Informa Connect’s Pharma/Biotech GTN Summit
(3d)
Drug Channels Leadership Forum 2027: Antonio Ciaccia to Serve as Moderator
(1w)
BlinkRx Insights: Beyond the Hub - Rethinking the Prescription Journey
(2w)
The Private Label Biosimilar Paradox in Medicare Part D
(2w)
Medicare, Medicaid, and Reverification: What Patient Support Programs Need to Know Before January 2027
(3w)
Drug Channels News Roundup, August 2026: 340B Rebate Model v2, Patients Feeling Drug Costs, Specialty Drug Spending Drivers, Impact on Coverage from the IRA, and a Drug Price Adventure
(3w)
Invisible Work of Rare Pharmacy Delivers Highly Visible Patient Outcomes
(4w)
REMS Removed: Why CAR-T’s Expansion into Community Oncology Could Benefit the Big Three Wholesalers
(4w)
Hub Transitions Need Proven Plans, Smart Scale-Up
(1mo)
The K-Shaped Pharmacy Shakeout: Consolidation in Cities, Lost Access in Rural America
(1mo)
Informa Connect’s Medicaid Drug Rebate Program Summit
(1mo)
A System of Record, or a System of Learning?
(1mo)
Who Will Pay for Prescription Drugs in 2034? Medicare's Surprising Rise in the Latest Government Forecasts
(1mo)
The Industry Doesn't Have an Access Collaboration Problem. It Has an Accountability Problem.
(1mo)
Drug Channels News Roundup, Mid-July 2026: Biosimilar Launch Strategy, Part D Spending Trends, Rural 340B Hospitals, What Employers Can Do About 340B, and Drug Channel Villains
(1mo)
Drug Channels News Roundup, July 2026: Biosimilar Launch Strategy, Part D Spending Trends, Rural 340B Hospitals, What Employers Can Do About 340B, and Drug Channel Villains
(1mo)
Direct-to-Patient: Transforming the Manufacturer Access Model
(1mo)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(1mo)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(1mo)
European Biotechnology Magazine
SLAS Journals Spotlight AI in Drug Discovery
(2h)
Sensorion files confidentially for potential U.S. IPO
(18h)
The Strüngmann legacy, passed on
(1d)
3PBIOVIAN Appoints Ponchi Kantt-Neaz as Global Executive Business Director
(1d)
ResoTher heart data clear acquisition hurdle, set up 200-patient trial
(1d)
GSK returns to Chimagen for up to $750M myeloma trispecific
(1d)
Agomab’s IPF drug clears first patient test
(2d)
MaaT’s bid to overturn microbiome approval refusal suffers setback
(2d)
Axoltis ALS drug misses Phase 2 endpoint
(2d)
Cellectis scraps CAR-T pipeline in gene editing pivot
(2d)
Genfit plans Phase 2 liver failure trial after acquiring immunomodulator from Inotrem
(2d)
GSK and Roche Chinese ADC bets deliver positive phase 3 data in SCLC
(2d)
BioNTech adds clinical weight to its oncology pivot at WCLC 2026
(3d)
Allogenetics adds €3.8M for rejection-resistant donor lungs
(6d)
Simris steps on Heidelberg Pharma’s toes with amanitin pivot
(6d)
EIB backs Ethris with €30 million for broad-spectrum antiviral mRNA
(6d)
Northway opens €61M Vilnius plant built for personalized medicine
(6d)
Connecta raises €3.1M for Fragile X syndrome Phase 2
(1w)
Teitur Trophics reports positive phase 1 data for Parkinson’s peptide
(1w)
Leyden Labs reveals RIGImmune acquisition with Phase 1 data
(1w)
Drug Hunter
enpatoran (M5049)
(19h)
pociredir
(1d)
How Pyridazinones Mimic Amides, Phenols, and Nicotinamides
(2d)
Lessons from Recently Approved Oral Small Molecules: Dose Regimens, PK, and Safety
(5d)
MK-1088
(5d)
diranersen
(6d)
TNG456
(1w)
EFMC Medicinal Chemistry 2026 First Time Disclosures
(1w)
Covalent Warhead Reactivity Cheat Sheet
(2w)
iberdomide (CC-220)
(2w)
golidocitinib (AZD4205 / DZD4205)
(2w)
Enlicitide (MK-0616)
(2w)
July 2026
(2w)
July 2026 Patent Gazette
(3w)
ACS Fall 2026 First Time Disclosures
(3w)
Beyond Molecular Design: How AI Agents Are Being Explored in Drug Discovery Workflows
(3w)
INN-Coming: Getting to Know the -Xetans
(3w)
atorvastatin
(4w)
iptacopan
(4w)
bepirovirsen
(4w)
Labiotech.EU
Oncology biotech news: key moves to watch in September 2026
(21h)
New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis?
(1d)
BIOSPAIN 2026: Spain’s flagship biotech event is going annual
(2d)
Beyond Ozempic: the GLP-1 landscape in 2026
(2d)
NLS Days 2026: what’s dealmaking like in the Nordics?
(5d)
Rewriting the rules of genetic medicine with tRNA therapeutics
(6d)
Preclinical Pulse: The research catching our eye in September 2026
(1w)
Eli Lilly’s pipeline in 2026: how the incretin boom is funding what comes next
(1w)
Streamlining stable cell line development from the start
(1w)
When every treatment counts: How clinical trials are changing the outlook for non-Hodgkin lymphoma patients
(1w)
Top biotech deals in August 2026
(2w)
How Evox Therapeutics is targeting CNS diseases with exosomes
(2w)
Bladder cancer treatment: where are we standing in 2026?
(2w)
The biggest biotech funding rounds in August 2026
(2w)
ESC 2026: The drug development readouts that stood out
(2w)
Investor confidence is built beyond the data
(2w)
How AOCs are advancing targeted therapeutics
(2w)
Six MASH biotech companies shaping the future of liver disease treatment
(3w)
BIOSPAIN 2026: partnering, policy, and the rise of Spanish biotech
(3w)
Genomes to bioreactors: Saudi Arabia’s gene editing oncology push
(3w)
Bio IT World
A 1970s Lipid-Lowering Compound May Offer a New Approach to Obesity
(1d)
Lehigh Team Uses Digital Twin of Gut-Brain Axis to Advance Neurostimulation Therapies
(2d)
What It Takes to Make Generative AI Fit for GMP
(6d)
Ultima, NVIDIA, Google Partner on Pangenome-Aware Whole Genome Sequencing
(1w)
Clearing the Bench-To-Bedside Hurdle: Why Translational Medicine Needs to Start Earlier
(2w)
NVIDIA Acquires Hugging Face for $12.93 Billion
(2w)
Deep-Learning Tool Uses Long-Read Sequencing to Detect Cancer Mutations
(2w)
Trends from the Trenches: Rethinking Computational Workflows for Modern Genomics
(2w)
What Scientists Actually Need From AI
(3w)
Follow the Money: Biological Foundation Models, Automated Bioanalysis, Predictive Cancer Care
(3w)
New CRISPR Screening Service, Calla Lily Joins Wellcome Leap’s Program, Baylor College to Establish Xenoliver Transplant Center
(3w)
Psychedelics Reveal Immune Signatures Linked to Rapid Depression Relief
(4w)
Multiomics Study Connects Clinical Phenotypes to Molecular Signatures in Down Syndrome
(4w)
Quality Leaders Warn Against Digitizing Broken Processes
(1mo)
The End of the ‘One-Size-Fits-All’ Parkinson’s Diagnosis: Why 2026 Is the Year Neurology Goes High-Resolution
(1mo)
Human Longevity Launches $600 Whole Genome
(1mo)
AI-engineered Vaccine Approach Could End Cycle of Variant Chasing
(1mo)
A Brain Orchestra … Playing at a Range of Unsynchronized Tempos
(1mo)
New CEO for PacBio, Updated Chemistry for Vega System
(1mo)
‘Reproductive Resilience Hypothesis’ Highlights the Ovary as a Discovery Source in Longevity Research
(1mo)
GEN News
Brain Protein in Mice Offers Insights Into Brain Development and ADHD
(13h)
Prophylactic Phage Therapy Protects Mice Against Oral Salmonella Infection
(14h)
Cellares and GenomeFrontier Therapeutics Partner to Advance Automated Manufacturing of GF-CART01
(15h)
Prime Assembly Expands Genome Editing with Precise, Large-Scale DNA Integration
(15h)
Red Light Supercharges Anti-Obesity Drug Precursor
(17h)
Choice of Excipients Dramatically Affects Antibody Solubility
(17h)
Lifecycle Approach Could Solve CGT Scale-Up Challenges
(17h)
Microprotein Atlas Links Brain Immune Cell Dysfunction to Alzheimer’s
(1d)
Exosomes Linked to Nerve Irritation, Dysfunction, and Lingering Pain After Shingles
(1d)
Right Resin, Right Order: A Two-Step Polishing Strategy for Bispecific Antibodies
(1d)
Consolidating Antibody Discovery Data with an AI Platform
(1d)
Evonik Expands in Slovakia
(2d)
Pneumococcal Subtypes Influence the Impact of Air Pollution on Disease Risk
(2d)
Why Does a Particular Genetic Variant Lead to Accelerated Huntington Disease Development?
(2d)
StockWatch: Novartis Loses More than Market Value After Phase III Failure
(3d)
Bone Marrow-on-a-Chip Model Offers New Window Into Immune Cell Development and Behavior
(5d)
CloudScope Enables Continuous Remote Monitoring of Brain Activity in Freely Moving Mice
(5d)
Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB Technology
(5d)
Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm
(5d)
Cancer Treatment Genetic Effects in Healthy Cells May Reveal Clues to Side Effects and Resistance
(5d)
Cure Today
Gentle Exercises to Keep You Moving During Cancer Treatment feat. Jennifer Tipton
(11h)
Imfinzi Plus Chemotherapy Raises 3-Year Survival to 69% in Gastric Cancer
(16h)
Childhood Leukemia Survivor Shares Her Experience With ALL, Relapse and CAR-T
(1d)
Echoes of the Battle: Navigating Post Cancer Trauma
(1d)
Enhertu in HER2-Mutant Lung Cancer: The First Year, Side Effects and Sequencing
(1d)
After His Daughter’s Cancer Treatment, AJ Wyman Realized He Needed Help, Too
(1d)
A Gift from the Sea
(1d)
Enhertu Delays Progression in HER2-Mutant Lung Cancer in Phase 3 Trial
(2d)
3 Trials Advancing Treatment Options for AML and MDS
(2d)
Tagrisso Shows 8-Year Survival Benefit in EGFR-Mutated Lung Cancer
(2d)
New Myeloma Combo Cuts Risk of Relapse by Up to 72% — Here's What It Could Mean for You
(2d)
Top 3 Takeaways From WCLC 2026 That Patients Should Know
(2d)
Why I Built a Garage Gym After Breast Cancer
(3d)
At 21 I Was Given 18 Months. This Year I Turned 40.
(4d)
What Cancer Survivorship Means to Me Now, Eight Years Later
(4d)
Why the First Denial of a Cancer Drug Isn't the Final Answer
(5d)
5 Years of Lung Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
(5d)
Why Patients With the Same Cancer Respond Differently to Treatment
(5d)
Cancer Drug Shortages Show Little Improvement in Fourth Year, New NCCN Survey Finds
(5d)
FDA Grants Final Approval to OMCAZIO, a New Capsule Formulation of Cabozantinib
(5d)
Contract Pharma
Gilead Partners With Pan American Health Organization on Lenacapavir Access for Latin America, Caribbean
(14h)
Thermo Fisher Launches SuperScript V Reverse Transcriptase
(14h)
Lilly TuneLab, Twist Bioscience Partner on Antibody Drug Discovery - contractpharma.com
(17h)
Piramal Pharma Plans Solar Power Plant in UK
(18h)
Hovione Doubles US Spray-Drying Capacity With Opening of New NJ Facility
(18h)
Shilpa Biologicals, SPIMACO Bio Ink MENA Biosimilars Deal
(20h)
Sanofi, UCB, Opella Join Clean Heat Program
(20h)
Ori Biotech Lands 10-Year, $120M Commercial Cell Therapy Manufacturing Deal
(1d)
CDMO Capacity: Stainless by Volume, Single-Use by Number
(1d)
Axiom, GeneFab Partner to Advance Therapeutic Pipeline
(1d)
Single Cell Discoveries Completes TATAA Biocenter Acquisition
(1d)
Cohance Lifesciences: A Global CDMO Platform with Multi-Modality Expertise
(1d)
Fareva Expands CDMO Network With Türkiye Site
(1d)
Asahi Kasei Launches VANTIJ SU-VFC Benchtop
(1d)
Chiesi Group Appoints David Khougazian as CEO
(1d)
Evonik Breaks Ground on New Biotechnology Expansion Project in Slovakia
(2d)
Vyome Welcomes Jerry Leonard as New Chief Financial Officer - contractpharma.com
(2d)
Syntegon Opens OSD Customer Center in Fellbach - contractpharma.com
(2d)
Symbiosis Names Jos Vergeest Senior Business Development Director - contractpharma.com
(2d)
SonoThera Appoints Adam Shaywitz Chief Medical Officer
(2d)
Pharma Times
Jemperli accepted for priority review by US FDA
(2w)
Carterra supports AI‑designed protein study with HT-SPR platforms
(2w)
Erasca secures FDA fast track for eras‑0015 in pancreatic cancer
(3w)
Avulux gains FDA authorisation for migraine light‑sensitivity lens
(3w)
Leqembi Iqlik launches in US for early Alzheimer’s
(3w)
Lundbeck gains EU orphan status for anti‑ACTH antibody
(3w)
AC Immune reports positive phase 1 data for ACI‑19764
(3w)
VarmX begins global phase 3 trial of VMX C001
(3w)
VarmX begins global phase 3 trial for VMX C001
(3w)
FairJourney Bio unveils tumor‑conditional IL‑12 breakthrough
(3w)
MHRA sets out position on microbiome‑based medicinal products
(3w)
US FDA accepts Teva’s new drug application for ecopipam
(3w)
NICE backs Axhidrox for severe underarm sweating
(4w)
Alzecure completes transaction with Lilly
(4w)
EffRx to commercialise Testavan in Switzerland
(4w)
Orpathys plus Tagrisso shows survival benefit in lung cancer
(4w)
Definium reports positive results for anxiety treatment
(4w)
Veppanu launch brings new option for advanced breast cancer
(4w)
First patient treated in new heavy‑chain‑only antibody trial
(1mo)
Novo Nordisk and AWS form AI partnership to speed drug discovery
(1mo)
Medcity News
Novartis Gains a Way to Get Drugs Into the Brain, Buying Sironax Tech for $125M
(15h)
As MA Denial Rates Rise, Hospitals Are Betting on Traditional Medicare Instead
(17h)
AI Isn’t a Therapist, but Many Teens Are Treating It Like One
(19h)
Hospital Margins Fell This Summer Amid Outpatient Slowdown, Data Shows
(1d)
Thatch Secures $108M, Reaches $1B Valuation
(1d)
GSK Commits $750M to Get Chimagen’s Phase 1-Ready Drug for Multiple Myeloma
(1d)
The Real Bottleneck in U.S. Pharma Reshoring Isn’t Factories – It’s Talent
(1d)
How Human-Led AI Improves Healthcare Marketing Intelligence
(1d)
Nara Health Secures $14M for Third Party Administration Platform
(2d)
Scholar Rock Drug Wins First-in-Class Approval in Rare Neuromuscular Disease
(2d)
Shadow AI Is the Fastest Growing Force in Medicine, and Hospitals Are the Only Ones Who Can Control It
(2d)
From Onboarding to Outcomes: The Privacy-First Identity Workflow for Pharma Marketing
(2d)
Interra Health Adds GLP-1 Bridge Program Support
(3d)
Inspiren Rakes In $70M to Scale Its AI-Powered Senior Living Platform
(3d)
Healthcare Needs Software That Handles a Messy Reality
(3d)
GenHealth.ai Raises $16.5M to Automate Healthcare Administrative Tasks
(5d)
Nutromics Nabs FDA Breakthrough Status for Antibiotic Monitoring Patch
(5d)
Augmenting the Systems That Support Patient Mobility
(5d)
3 Strategies to Improve Health Insurance, Per Georgetown Report
(6d)
Imprivata CEO: AI Agents Need the Same Scrutiny as an Unvetted Contract Nurse
(6d)
Chemical & Engineering News
Why the Reflecting Pool coating peeled and blistered
(12h)
What did a group of Priestly Medalists have to say about the future of chemistry?
(18h)
Comment: Building stronger local sections for the future
(20h)
Editorial: We can have both prosperity and sustainability
(23h)
Groups cite huge health costs from EPA’s power plant GHG rollback, vow to sue
(1d)
Skeletal editing can transform molecules’ biological activity
(1d)
Business Watch: European pyrolysis plants get new owners, and more
(1d)
Custom genetic codes can now be created with ease
(1d)
Periodic Graphics: How do friction-erasable pens work?
(1d)
Learn something
(1d)
Chemistry in Pictures: Controlling colors
(2d)
Hyaluronic acid could cut cancer risk, if we can get around its cons
(2d)
ACS Northeastern Section seeks Gustavus John Esselen Award nominations
(5d)
Policy Watch: US Treasury targets private school DEI programs
(5d)
Hokkaido University is cited in fatal HF accident
(5d)
Constructing cyclopropanols, one carbon at a time
(5d)
Aerosols’ acidic conditions favor some diastereomers over others
(5d)
C&EN weekly chemistry news quiz, Sept. 11
(6d)
ACS seeks nominations for the 2028 ACS National Awards
(6d)
This recyclable tape is stronger than duct tape
(6d)
The Pharma Letter
Boehringer halts Phase III kidney trial of vicadrostat/Jardiance combination
(51m)
ICER releases evidence report on treatment for Parkinson’s disease
(16h)
Vivan and Ad Atomica pair tumor genotype data with AI drug design
(16h)
Sling Therapeutics announces $123M financing
(19h)
Top-20 Novartis shareholder demands board shake-up after back-to-back trial failures
(19h)
Remepy welcomes new CMO to advance hybrid drug pipeline
(19h)
FDA unveils expedited IND pilot, begins accepting applications
(22h)
Lundbeck wins Japanese approval for Vyepti
(22h)
LB Pharma hires Susan Kozauer as CMO
(22h)
Lundbeck wins Japanese approval for Vyepti
(22h)
FDA approves additional information in labeling for Kybella
(23h)
Why PDUFA VIII keeps patients first and strengthens America's biopharma leadership
(23h)
Shilpa Bio inks deal for PD-1 biosimilar for MENA market
(23h)
What drug shortage lists show in 2026, and what they leave out - thepharmaletter.com
(1d)
RegCell banks $66 million to take Nobel-winning Treg work into clinic - thepharmaletter.com
(1d)
RegCell banks $66 million to take Nobel-winning Treg work into clinic
(1d)
Ascendis regains obesity rights as Novo exits monthly GLP-1 deal - thepharmaletter.com
(1d)
Realizing the promise of RWE: A need for greater regulatory clarity - thepharmaletter.com
(1d)
Diasome reshapes leadership team as HDV-Insulin heads toward Phase III - thepharmaletter.com
(1d)
Sandoz issues 500 million euros bond to extend debt maturity profile
(1d)
Targeted Oncology
After the First ADC Fails, HR-Positive Breast Cancer Sequencing Runs on Judgment, Not Trial Data
(12h)
Tam-Peli Extends Survival in Relapsed Small Cell Lung Cancer
(15h)
FDA Accepts Bezuclastinib NDA for Advanced Systemic Mastocytosis
(17h)
Sacituzumab Govitecan Combo Misses PFS End Point in PD-L1–High NSCLC
(18h)
Rib-Sparing Approach Lowers Post Thoracotomy Pain
(19h)
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
(20h)
T-DXd Significantly Improves PFS in First-Line HER2-Mutant NSCLC
(1d)
Gotistobart Nearly Doubles Median OS vs Docetaxel in Squamous NSCLC
(1d)
FDA Approves Lutetium Lu 177 Dotatate Injection for SSTR-Positive GEP-NETs
(1d)
Integrating Frontline Biomarkers and Multidisciplinary Teams in Prostate Cancer
(1d)
Adjuvant Osimertinib Sustains 8-Year OS Benefit in Resected EGFR+ NSCLC
(1d)
Jeff Sharman, MD, on Advances in Non-Hodgkin Lymphoma Treatment
(1d)
Reading Duration of Response Across ROS1 Inhibitor Trials
(1d)
Amivantamab-Chemotherapy Shows Longest OS Reported in EGFR Exon 20 NSCLC
(1d)
Intracranial Control and Radiation Sparing in ROS1-Positive NSCLC
(1d)
Rethinking HER2: A Pan-Cancer Look at IHC, ERBB2, and Tumor-Agnostic Testing
(2d)
FDA Approves Aminolevulinic Acid Gel With PDT for Superficial Basal Cell Carcinoma
(2d)
Camizestrant Plus Palbociclib Misses PFS End Point in SERENA-4 Trial
(2d)
FDA Approves Pixclara, First FET-PET Agent for Glioma Imaging
(2d)
Risvutatug Rezetecan Shows 54% OS Improvement in Relapsed SCLC
(2d)
MedWatch
Lundbeck Foundation secures more votes through share exchange
(29m)
New CEO appointment eases strategy concerns at Bavarian Nordic, Jefferies says
(30m)
Bavarian Nordic names new CEO
(50m)
Ascendis faces financial setback after patent dispute – Yet the CEO sees the outcome as a victory
(3h)
WSA chair supports call for new CFO to have IPO experience: Nevertheless says it's not decisive
(20h)
Scandinavian Medical Solutions' CEO steps down as part executive reshuffle
(20h)
Novo forms partnership with Anthropic
(21h)
WSA recruits new CFO from Novo
(21h)
Abacus aims to double its Polish acquisition: Growth must now be more profitable
(22h)
Ascendis CEO after scrapped Novo partnership: Big mistake to be dependent on Big Pharma
(22h)
Former Novo CEO recalls the day he was fired: "It happened on a Sunday"
(1d)
New diet pill with fewer side effects matches Lilly's results
(1d)
Novo top outlines new principles: "We need to broaden"
(1d)
US health nominee backs MMR vaccine, breaks with Trump’s comments
(1d)
Lundbeck wins Japanese approval for migraine drug Vyepti
(1d)
Eli Lilly fined for marketing an unapproved drug
(1d)
Eli Lilly: We account for more than 30% of new US patients on pill-based treatment for obesity
(1d)
Zealand Pharma licenses drug to US-based Elvinix
(1d)
Novo still seeks a long-acting treatment after scrapped deal with Ascendis
(2d)
Eli Lilly halts early-stage obesity drug development
(2d)
In The Pipeline
The ACS Redesign
(1d)
Not The Glue They Thought It Was
(2d)
The State of AI Antibody Design
(5d)
Phosphorylate and Spare Not
(6d)
More Impossible-to-Ignore Vaccine Effects
(1w)
GLP-1 Drugs for Aging?
(2w)
Mutate 'Em All and See If You Can Sort 'Em Out
(2w)
Crappy Antibodies, Made Superficially More Appealing
(2w)
The Alleged Dimethylmercury Incident
(2w)
On vacation until August 31
(3w)
The Fault Is Not In Our Trees, But In Ourselves
(4w)
Merck and Moderna's Melanoma Results
(4w)
More Alzheimer's Research Trouble
(4w)
A New Alzheimer's Therapy - Or Is It?
(1mo)
The Proposed Changes in Childhood Vaccination: A Strongly Felt Opinion
(1mo)
So How Is AI Drug Discovery Doing, Really?
(1mo)
This Is Why We Run Trials, Unfortunately
(1mo)
Put Your Money Down, They Say
(1mo)
Target Practice on the Molecular Scale
(1mo)
We Only Know Her as Mei
(1mo)
Pharmaphorum
NICE finally backs Enhertu for HER2-low breast cancer
(37m)
Novo taps Anthropic's Claude AI for drug discovery
(1h)
Wales takes UK lead on needle-free anaphylaxis prevention
(17h)
Legend Biotech names ex-Novartis exec as CEO
(20h)
TikTok parent ByteDance raises cash for drug AI spinout Anew
(21h)
AI spots drugs that may be repurposed for priority pathogen
(22h)
FDA unveils framework for its expedited IND pilot
(23h)
FDA backs Curium's Bexlutry as 1st 'radioligand equivalent'
(1d)
Electra sets terms for IPO, hoping to raise up to $347m
(1d)
GSK wagers $750m on Chimagen multiple myeloma therapy
(1d)
Chiesi fills permanent CEO role with Flagship's Khougazian
(2d)
FDA to decide on Takeda's psoriasis blockbuster hope in Q1
(2d)
WCLC: Lung cancer news from BioNTech, Akeso, and Roche
(2d)
GSK showcases positive data with lung cancer drugs at WCLC
(2d)
AZ's Etcamah falls short in first-line breast cancer trial
(2d)
Scholar Rock gets first drug approval as FDA okays Isembyld
(3d)
Resistance grows to Recordati's private equity takeover
(3d)
Novo Nordisk rebrands as Novo as new CEO charts turnaround
(3d)
Hengrui gets world-first okay for platelet drug hetrombopag
(5d)
Andy Plump to step down as Takeda's R&D chief
(6d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(3mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(3mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(3mo)
Therapy enables 89% survival rate in myeloma patients
(3mo)
Ulcerative colitis treatment shows best-in-class potential
(3mo)
UK patients to benefit from approval of weight loss tablet
(3mo)
Vertex presents new data on Casgevy in children
(3mo)
DDW Highlights: 16 June 2026
(3mo)
LXR inverse agonist shows promise in liver disease
(3mo)
Guide: One solution – from R&D, to QC
(3mo)
A potentially practice-changing advance in bile duct cancer
(3mo)
Webinar: Consolidate multiple assays into a single, comprehensive AVA test
(3mo)
JAK inhibitor for VEXAS syndrome gets orphan drug designations
(3mo)
Whitepaper: How workflow scheduling software can answer the demands of automated labs
(3mo)
PhoreMost advances brain cancer programme to trial
(3mo)
Oriva appoints Arbat as CEO, advances endometriosis asset
(3mo)
Decoding Pan-RAS(ON) inhibitor activity across KRAS models: Webinar
(3mo)
This week in Drug Discovery (8 June – 12 June)
(3mo)
Laverock reports positive data from oncology programmes
(3mo)
GSK acquires Nuvalent and cancer therapy pipeline
(3mo)
HIT Consultant
M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care
(15h)
Biohacking’s Gender Problem: Why Women’s Health Protocols Require Dedicated Research and Clinical Variables
(18h)
R1 Unveils Phare Utilization Management on Phare OS to Eliminate Medical Necessity Denials
(18h)
M&A: MRO Acquires Vyne Medical to Expand Intelligent Healthcare Intake Automation
(20h)
FDA Awards Cognita Imaging $1.29M to Validate LLM-as-a-Jury Evaluation Across 1 Million Radiology Reports
(20h)
Cedar Gate Survey Reveals 83% of Health Plans Miss VBC Outcomes Due to Fragmented Data
(22h)
Rutgers, RWJBarnabas Health, and AWS Launch Innovation Hub at HELIX
(22h)
Healthcare’s Cyber Playbook Was Built for Another Era. Here’s How Leaders Can Adapt
(23h)
MEDITECH Completes Expanse Implementation Across 34 Hospitals in HCA Healthcare’s First Two U.S. Divisions
(1d)
Thatch Reaches $1 Billion Unicorn Valuation with $108M Raise to Expand Personalized Health Benefits
(1d)
Imprivata Report Reveals 72% of Healthcare Organizations Run Unapproved AI as Autonomous Agents Enter Clinical Care
(1d)
Amazon One Medical Expands On-Demand GLP-1 Care to 48 States & Washington, D.C.
(1d)
M&A: Hello Patient Acquires Converse Health to Unify Outpatient Front-Office Voice with Back-Office EHR Automation
(1d)
The ROI of Simplicity: Why Less Digital Friction Delivers More in Healthcare
(1d)
M&A: Medallion Acquires Andros to Unify One Million Providers onto an AI-Native Credentialing Platform
(1d)
Quantum Health Appoints Dr. Susan Mani as Chief Medical Officer
(1d)
GE HealthCare Launches CareIntellect for Operations to Deliver 72-Hour Predictive Inpatient Capacity Forecasting
(1d)
Why Asset Visibility Is Healthcare’s Next Operational Advantage
(2d)
Inspiren Secures $70M to Scale Physical AI Across Senior Living
(2d)
Abridge Enters the Mid-Revenue Cycle with Pre-Bill AI for CDI and Coding Teams
(2d)
Insights: Pink Sheet
No Letup In Aging Japan’s Rising Health, Drug Costs
(6h)
OTC Industry Makes First PDUFA Appearance After Months of Behind-the-Scenes Negotiations
(9h)
Big Pharma CEOs Bullish On US Policy Environment Heading Into Midterm Elections
(11h)
PDUFA VIII’s ‘America First’ Fee Incentives Could Be Gamed, Stakeholders Warn US FDA
(13h)
FDA Nominee Heidi Overton Could Appear Before Senate Panel As Soon As Sept. 24
(13h)
EMA Backing Unlikely For MaaT’s Microbiota Therapy After Negative Trend Vote
(16h)
Orphan Drug Hopefuls Navepegritide And Norucholic Acid Face EMA Oral Explanations
(18h)
Zealand’s Glepaglutide Faces Crucial EMA Hearing After US Setback
(18h)
HHS Nominee Klomp Faces Democratic Gauntlet On MFN Deals’ Secrecy, Vaccines At Hearing
(1d)
Gene-Silencing Therapies Face Different Bar Under US FDA Plausible Mechanism Framework
(1d)
China Security Fears Could Delay PDUFA Reauthorization, US FDA Warns
(1d)
Ovarian And Lung Cancer Therapies Await EMA Verdict After Wins In US, China
(1d)
High-Stakes EU Opinions Loom For JCA Listed Cancer Drugs Relacorilant, Senaparib And Ensartinib
(1d)
Novo Eyes EMA Nod For Denecimig After Securing Saudi Approval
(1d)
US FDA Will Select Up To 10 Sponsor-Institution Pairs For Expedited IND Pilot
(1d)
Gilead HIV Drug Dispute: Canadian Court Leaves ‘Door Open’ To Novel Liability Claims
(2d)
MFN Pricing Policy Not Designed For Cell, Gene Therapies, CMS Advisor Says
(2d)
Domestic Manufacturing Incentives Join CDER Director Mike Davis’ Quality Agenda
(2d)
Rare Diseases: US FDA Looking For Ways To Increase Appeal Of Randomized Trials
(2d)
US Vaccine Guidance Paralysis Leaves Moderna’s mFlusiva Without A Launchpad
(2d)
BioXconomy
FDA to boost overseas trial site inspections amid concerns about regulatory oversight capacity
(12h)
RegCell banks $66m to advance Nobel-winning immune tolerance platform
(17h)
Japan’s hybrid DCT approach shaped by unique regulations, healthcare system, and geography
(18h)
GSK bets up to $750m on Chimagen's multiple myeloma treatment
(23h)
Shennon lands $12m and new CEO to drive immunotherapy pipeline forward
(1d)
Transcript in the machine: How AI paved the way for customized mRNA cancer treatments
(1d)
How mRNA could change the battle against tuberculosis
(2d)
Peptide therapy triumphs in Phase I Parkinson’s trials
(2d)
Eyes on Asia: Solstice, Gan & Lee, NeuShen Therapeutics
(2d)
nPhase launches AI platform to speed regulatory submissions for clinical trials
(2d)
Barcelona biotech funding to tackle leading cause of inherited intellectual disability
(2d)
How corporate VCs are rewriting the rules of biopharma investment
(3d)
From childhood friends to microbiome pioneers: Inside GutGutGoose's journey
(3d)
Kura forms Lilly-backed spinout with $50m to develop diabetes drug
(5d)
Encoded lands $275m Series F to push Dravet gene therapy into trials
(6d)
Gilead and Bayer leaders on relationship-driven compliance monitoring
(6d)
Luma Group closes $410m life sciences fund, eyes US-EU-Israel deals
(6d)
Novartis suffers double blow as muscular dystrophy AOC drug fails clinical trial
(6d)
Influencer marketing could aid clinical trial recruitment, study finds
(6d)
Life sciences deals surge to $196bn with early-stage asset demand
(1w)
BioCentury
Academic deals stay close to home
(9h)
Science Spotlight: A macrophage-recruiting bispecific, plus new tactics against TCR-T escape and tumor stroma
(12h)
Sleep deals cluster in narcolepsy and sleep apnea
(13h)
FDA fills in blanks on expedited IND pilot
(1d)
Novartis commercial leader Ingrid Zhang named Legend CEO
(1d)
FDA signals tighter scrutiny of early-stage data from China
(1d)
Lazard’s Gluckman: Annual survey hints at ‘change in architecture’ across industry
(2d)
Psychedelics at FDA, Mike Davis’ CDER and translating tRNAs — a BioCentury podcast
(2d)
AZ’s camizestrant miss narrows oral SERD treatment settings
(2d)
Suppressor tRNAs take two translational steps forward
(2d)
FDA could approve psychedelics before redosing is resolved
(2d)
Takeda’s Plump, GV’s Yeshwant announce retirement plans
(5d)
With deep pockets, Solstice takes next-gen CTLA-4 into neoadjuvant treatment
(5d)
Encoded preps for Dravet launch with $275M round: Finance Report
(5d)
Letter from the Editor: FIH data — is now the time for change?
(5d)
Novartis DM1 miss raises stakes for next wave of DMPK readouts
(6d)
Biotech’s 2026 IPOs deliver broad gains through August
(6d)
Science Spotlight: Multiple sclerosis genetics point inside the brain
(6d)
Novartis’ growth drivers, beyond the setbacks
(6d)
Michael Davis: A firm hand on CDER’s tiller
(1w)
SCRIP
Roivant’s Push To Become More Than A Pipeline Story
(49m)
Amgen Confident In Cardiometabolic Pipeline After Novartis’s Negative Lp(a) Readout
(11h)
Novartis’s VHB937 Latest To Join ALS Clinical Development Graveyard
(12h)
Big Pharma CEOs Outline US Policy Goals Heading Into Midterm Elections
(13h)
Sling Raises $123m As It Takes Oral TED Drug Contender Into Phase III
(16h)
Pfizer CEO Warns China May Follow US To Limit Biotech Deals
(17h)
The Challenges Facing New Chiesi CEO Khougazian
(19h)
Senlang/Tempest Option Marks China’s First Global Deal For In Vivo CAR-T
(1d)
WCLC 2026: Leads Eyes Phase III For Novel Bispecific After Promising 1L NSCLC Data
(1d)
Arrowhead Tackles Two Targets To Lower Multiple ASCVD-Causing Lipids
(1d)
Phase II Depression Failure May Close Door On Contineum/J&J’s M1 Antagonist
(1d)
Vera’s Trutakna Gains Early Market Share As Phase III IgAN Data Put It On Par With Voyxact
(1d)
Legend Appoints Ingrid Zhang To Usher In Next Cell Therapy Era
(1d)
WCLC 2026: BioNTech’s Gotistobart Looks Closer To Big Win In NSCLC
(1d)
Stock Watch: Rookie Mistakes In Product Valuation
(1d)
GSK Taps Chimagen To Enter Trispecific Multiple Myeloma Territory
(1d)
Definium’s Second Anxiety Trial Win Pushes Psychedelic Race Into Final Stretch
(1d)
BioVie Plans Phase III Study After Long COVID Drug Shows Subgroup Signals
(1d)
WCLC 2026: Ivonescimab OS Win Sets High Bar For Other Keytruda Rivals In 1L NSCLC
(2d)
Cullinan/Taiho’s Zipalertinib Ready To Challenge Rybrevant In NSCLC
(2d)